BioCentury
ARTICLE | Emerging Company Profile

Catching antibodies with polymers

How Polyneuron’s glycopolymers could treat autoimmune and other diseases

August 8, 2018 6:40 PM UTC

Polyneuron Pharmaceuticals AG's glycopolymers act as decoys for the autoantibodies that drive autoimmune diseases, such as anti-MAG neuropathy, and are designed to be more effective and safer than other therapies.

Polyneuron's Antibody-Catch platform generates glycopolymers that mimic the epitopes found on an autoantibody’s cognate antigen. CSO Pascal Hänggi said the compounds are based on a homoamino acid polymer with carbohydrate groups attached to it and contain a single epitope mimetic that decoys autoantibodies, binding and eliminating them...